- Independent Data Safety Monitoring Board (DSMB) confirms the acceptable safety profile of Donesta® and recommends to continue the Phase III Clinical Program as planned
- On track to target marketing authorization in 2023
- Consolidation of business development strategy of Donesta® by successful major funding transactions in 2020
Liege, Belgium, 16 December 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that its independent Data and Safety Monitoring Board (DSMB) completed its end-of-year safety assessment of the Phase III Clinical Program of Donesta®, a next generation orally-administered E4-based hormone therapy product candidate for the relief of menopausal vasomotor symptoms (VMS).